Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06267209
Other study ID # He-Modulation
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date May 1, 2024
Est. completion date June 20, 2024

Study information

Verified date May 2024
Source Investigación en Hemofilia y Fisioterapia
Contact Rubén Cuesta-Barriuso, PhD
Phone 607547274
Email cuestaruben@uniovi.es
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Introduction: Hemophilic arthropathy is characterized by functional alterations, disabling physical sequelae, and chronic pain. Conditioned pain modulation describes the net effect of endogenous pathways that enhance or diminish the effects of afferent noxious stimuli. Objectives: To describe conditioned pain modulation in patients with hemophilia and identify the best predictive model of conditioned pain modulation in these patients Methods: Cross-sectional cohort study. 51 patients with hemophilic arthropathy will be recruited in 3 regions of Spain. The main study variable will be the conditional pain modulation (Conditioned Pain Modulation Index, using an ischemic technique of the arm using the pain pressure threshold as a test stimulus), with age being the dependent variable. The secondary variables, estimated as modifying or confounding variables, will be kinesiophobia (Tampa Scale for Kinesiophobia), catastrophizing (Pain Catstrophizing Scale), trait and state anxiety (State-Trait Anxiety Inventory) and the main clinical, anthropometric, and sociodemographic. Expected results: Identify the degree of modulation conditioned by pain in patients with hemophilic arthropathy. Identify the best predictive model for conditioned pain modulation in these patients based on the study variables


Recruitment information / eligibility

Status Recruiting
Enrollment 51
Est. completion date June 20, 2024
Est. primary completion date June 3, 2024
Accepts healthy volunteers No
Gender Male
Age group 20 Years to 65 Years
Eligibility Inclusion Criteria: - Patients diagnosed with hemophilia A or B. - Patients over 18 years of age. - Persons with a medical diagnosis of bilateral hemophilic ankle arthropathy. - Patients with clinical assessment by Hemophilia Joint Health Score (>4 points). - Persons with hemophilia on prophylactic treatment with FVIII / FIX coagulation concentrates or monoclonal antibodies. - Have signed the informed consent document. Exclusion Criteria: - Patients with neurological or cognitive alterations that prevent the comprehension of the questionnaires and physical tests. - Patients who have had an ankle hemarthrosis in the 6 months prior to the start of the study. - Patients who have taken analgesic or anti-inflammatory drugs in the 30 days prior to the study. - Patients who are undergoing an intervention (physiotherapeutic or orthopedic) at the time of the study.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Observational group
After confirming that the patients not meet any of the exclusion criteria, dependent and confounding study variables will be assessed. Patients will be recruited in 3 regions of Spain (Galicia, Madrid and Malaga), through the respective provincial associations and the Spanish Federation of Hemophilia. The assessment will take place at the premises of the hemophilia associations included in the study. All the evaluations will be carried out by the same physiotherapist, following the same evaluation protocol. The primary variable of the study will be the conditioned modulation of pain, being age the dependent variable. Secondary variables, estimated as modifiers or confounders, will be kinesiophobia, catastrophizing, anxiety perception, joint damage, pain intensity, functional capacity and pain threshold to pressure, and type of treatment and development of inhibitors.

Locations

Country Name City State
Spain University of Oviedo Oviedo Asturias

Sponsors (1)

Lead Sponsor Collaborator
Investigación en Hemofilia y Fisioterapia

Country where clinical trial is conducted

Spain, 

Outcome

Type Measure Description Time frame Safety issue
Primary Assess the Conditioned Pain Modulation Index First, we will measure the pain threshold to pressure at the base of the dorsal part of the distal phalanx of the thumb, and then we will provoke the conditioned stimulus using the ischemia test on the contralateral upper limb. For the ischemia test, a sphygmomanometer will be used and inflated to 240 mmHg. The arm will be positioned horizontally. Patients will be asked to indicate the intensity of pain on a numerical pain rating scale until a pain rating of 7/10 appears. Patients will perform resistance exercises in wrist extension by lifting a 2 kg weight up to a maximum of 45 repetitions. With the sphygmomanometer still inflated, pain detection threshold measurements will be repeated at the dorsal aspect of the distal phalanx of the thumb. The time shall not be extended beyond six minutes. Screening visit
Secondary Assess the kinesiophobia with Tampa Scale of Kinesiophofia With the Tampa Scale of kinesiophobia (TSK-11SV) questionnaire, the fear of movement of the patients included in the study will be evaluated. It consists of 11 items. Its values have a range of 1 to 4 points, where the higher the score, the greater the fear of movement Screening visit
Secondary Assess the catastrophizing with Pain catastrophizing scale With the Pain catastrophizing scale questionnaire, the catastrophizing of patients with congenital coagulopathies will be measured. The scale, made up of 13 items, is assessed with a range of 0 to 4 points (lower score indicates less catastrophism). Screening visit
Secondary Assess the catastrophizing with State-Trait Anxiety Inventory With the State-Trait Anxiety Inventory (STAI) scale, the perception of anxiety of the patients included in the study will be measured. The state and the anxiety trait of each subject are evaluated with a score of 0 to 30 points for each scale, where a higher score indicates a higher anxiety index in the trait or state. Screening visit
Secondary Assess the joint damage with Haemophilia Joint Health Score With the Hemophilia Joint Health Score scale, specific for its use in patients with hemophilia, the joint status of patients with hemophilic arthropathy will be evaluated. It evaluates 8 items: inflammation and duration of this, pain, muscle atrophy and strength, crackles, and loss of flexion and extension. It has a score of 0 (no joint damage) to 20 points (maximum joint damage) per joint (elbows, knees and ankles). A gait rating is added to the 120 points (range 0-4 points), the maximum rating on this scale being 124 points Screening visit
Secondary Assess the joint pain with visual analog scale The visual analog scale will be used to assess the perception of joint pain, being valued with a range of 0 to 10 points (from no pain to the maximum pain suffered or imaginable) in the joints evaluated Screening visit
Secondary Assess the pressure pain threshold with pressure algometer With a pressure algometer (model Wagner FPN100) we will measure the pressure pain threshold, at the joint level and at a distance (in another part of the body). This device measures in Newton / cm2 the pressure at which the subject perceives pain under pressure. A pressure will be made on the chosen point, which we will increase at an approximate speed of 50kPa / s until the patient warns us that the sensation begins to be painful. We will be assessed in ankle (lateral malleolus, L5 spinous process, and extensor carpi longus muscle). Screening visit
Secondary Assess the functional capacity with the 6-Minute Walking test The 6-Minute Walking test is performance-based, measuring walking speed and submaximal exercise capacity. Patients are instructed to walk a 30 to 50 meter track for 6 minutes and try to cover as much distance as possible without running. The distance covered, in meters, in 6 minutes is recorded, allowing the use of a walking aid or orthosis. Screening visit
See also
  Status Clinical Trial Phase
Recruiting NCT05617209 - In Vitro Correction of Thrombin Generation by Concizumab (Anti-TFPI) for Severe Hemophilia Patients
Completed NCT05039008 - Restricting Blood Flow in Improving Muscle Strength in Patients With Hemophilic Arthropathy N/A
Recruiting NCT04398628 - ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disorders
Completed NCT02546622 - ATHN 2: Factor Switching Study
Unknown status NCT02165592 - Assessment of Proprioceptive and Functional Characteristics in Patients With Hemophilia N/A
Completed NCT02165462 - Bilateral Deficit Phenomenon in Patients With Haemophilic Arthropathy N/A
Terminated NCT02586012 - Weight-based Dosing in Hemophilia A Phase 2
Unknown status NCT02433782 - Myofascial Therapy in Patients With Hemophilic Arthropathy N/A
Completed NCT01232634 - Validation of Ultrasound as a Diagnostic Tool for Assessment of Hemophilic Arthropathy of Knees and Ankles Phase 2
Completed NCT05104164 - Self-myofascial Release in Hemophilic Ankle Arthropathy N/A
Terminated NCT01191372 - First-in-Human and Proof-of-Mechanism Study of ARC19499 Administered to Hemophilia Patients Phase 1
Completed NCT05173129 - Posture Analysis for Patients With Haemophilia N/A
Completed NCT03818529 - ATHN 8: Previously Untreated Patients (PUPs) Matter Study
Withdrawn NCT03996486 - Study to Test the Safety of an Investigational Drug Given Repeatedly to Adult Men With Severe Hemophilia Phase 1
Completed NCT01708564 - A Phase I Safety, Pharmacokinetics and Pharmacodynamics Study of Recombinant Factor VIIa in Adult Patients With Hemophilia A or B Phase 1
Completed NCT03842605 - Efficacy of Strength Training in Improving Elbow Range of Motion and Function in Adults With Hemophilia N/A
Completed NCT05549843 - Manual Therapy in the Treatment of Hemophilic Arthropathy of the Ankle N/A
Recruiting NCT06010953 - SS109 and NovoSeven ® PK / PD Profile, and Preliminary Efficacy and Safety of SS109 on Demand Treatment Phase 1/Phase 2
Completed NCT05027230 - A Safety and Efficacy Study of STSP-0601 in Adult Patients With Hemophilia A or B With Inhibitor Phase 1/Phase 2
Not yet recruiting NCT06014320 - Alterations in Coagulation Factor Levels in Patients With End Stage Liver Disease